Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...

Hims & Hers is a telemedicine platform that offers patients access to a variety of medications, including for skin care, anxiety, sexual health, and even weight loss.

Hims & Hers is a telemedicine platform that offers patients access to a variety of medications, including for skin care, anxiety, sexual health, and even weight loss.

Hims built its U.S. business by turning taboo subjects (hair loss, erectile dysfunction, anxiety) into approachable subscription kits, then upselling adjacent therapies once trust is established.

Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.

Hims offers one of the fastest and easiest ways to get prescription medication for anxiety and depression. And it’s one of the only places where you can get a psychotropic medication ...

Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a fraction of the cost of brand-name competitors such as Wegovy and Ozempic.

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after revenue more than doubled, and it raised full-year guidance. Revenue hit ...

Hims & Hers' Q1 earnings Hims & Hers reported a surge in sales in the first quarter of 2025, up 111% year over year at $586 million. (Wall Street only wanted $539 million, but isn't complaining.) ...